Aug 23, 2021 | 2021, Press Releases, Scientific
Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read MoreJul 2, 2021 | 2021, Press Releases, Scientific
Fibromun shows activity in pretreated glioma and sarcoma patients; OncoFAP targets tumor lesions in cancer patients; a new product partnered with AbbVie entered clinical studies Read moreMay 12, 2021 | 2021, Press Releases, Scientific
COMUNICATO STAMPA 05-12-2021 PRESS RELEASE – 2021-05-12May 4, 2021 | 2021, Press Releases, Scientific
Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer. Philogen announces participation to the 10th World Congress of Melanoma...Jan 13, 2021 | 2021, Press Releases, Scientific
NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned. PRESS RELEASE – 13/01/2021Oct 8, 2020 | 2020, Press Releases, Scientific
PRESS RELEASE
Recent Comments